Earn 8.00 - 12.00% Interest. Great Returns. No Banks. $25 Sign-Up Bonus.

One Guy's Investments

The story of Travis Johnson's investment portfolio, with analysis and thoughts on the stocks and funds I've considered, bought and sold. I don't claim to have brilliant picks that will make you money, and I'm not an investment advisor, registered or otherwise, so don't follow my moves unless you're happy to lose money without suing someone. I'm just one guy. My articles get republished in several places, but always appear here first -- subscribe now(totally free via RSS) to see them before they're on Yahoo Finance.

Saturday, November 19, 2005 -- Subscribe free

Interesting Morningstar Series

Morningstar has recenty run a few stories about a research project they're doing on growth stocks -- definitely worth a read.

The first article, How Much Should You Pay for a Growth Stock, explains what they're doing (for the full research data and articles you have to subscribe to their premium services). Basically, they went back to 1995 and looked at the growth stocks from that year that are still in existence today (and for the most part, still considered growth stocks today). They applied their "margin of safety" assumptions and determined what price you could have paid for those stocks and still had a ten year (roughly) return to date that beat the market's roughly 11% return for that time period. They're doing this for shorter time periods, too, beginning in 2000 and 2005, and I hope they publicize that information as well -- it'll be interesting to see what this means for shorter holding periods.

The results are pretty remarkable -- the chart lists a lot of companies that we've all heard of and gives their PE at the time and the PE you could have paid for them and still beat the market for your 10+ year holdling period.

A few really piqued my interest that are in my portfolio or have been in the past -- Chicos (CHS), for example, was trading at a PE of about 12 ... but you could have massively overpaid for it and got it at a PE of 491 and you would have STILL beat the market. Goes to show you how much one great stock can mean to a long term portfolio.

Of course, no need to tell that to Dell fans -- they may have felt nervous about that PE of 18 for a small computer company with lots of competition, but it turns out they would have beaten the market even if they paid up to a PE of 350.

In plainer terms, the split adjusted price of CHS was 28 cents, but even if you had paid over $11 you would have still beat the market. For Dell, it was 64 cents and you could have paid over $12 and still had better than an 11% annual return. Pretty remarkable.

Companies like Motorola, or Coca Cola, however, didn't fare so well -- anyone who has held those for ten years, or many others on the list, has failed to beat the market and maybe even lost money.

Part two of the same article gives some preliminary conclusions, and while they have the kind of stodginess that sometimes turns folks off from Morningstar, they also make a lot of sense.

What do they recommend? Well, read the article ... but, basically, we should still look for a margin of safety in the purchase price, growing future demand for the product or service and a growing competitive advantage (moat), and growth-oriented management.

I think I've gotten better and looking for some parts of that -- the growing future demand and growing moat are key considerations and they coincide with the "story" or "theme" of a stock, business or industry, the part that I find interesting to research.

The part that I have trouble with is the buying price -- since I'm usually interested in finding companies that have real potential to show dramatic growth, I have an awful time computing a margin of safety in the price I pay for a company. I often fall back on the PEG ratio, which Peter Lynch really liked (Price/Earnings/Growth -- basically, is the PE ratio higher or lower than the future growth rate), but I find myself trying to estimate future growth for a company because I don't often put a lot of stock in analyst growth predictions, especially for the very small companies that I'm most likely to get interested in and that seem to be very capable of blowing through analyst numbers (or cratering when the miss them on the flip side, of course).

I guess that's where I need to do me some more book learnin' -- I've been paying attention to the Motley Fool's great investor education materials, and they seem to follow a lot of the same strictures as Morningstar in dealing with free cash flow and discounting, and their investor education center has some good articles on cash flow-based valuation and similar topics. The discounting aspect of it is pretty simple math as long as you've got a calculator handy, so we're all capable of that.

And that, finally, is the problem with having a diversified portfolio with a large number of stocks, as I do -- I'm not going to rerun a disounted cash flow analysis for every company every quarter, or even every year, so I focus probably a little more than I should on themes, stories, and PEG ratios even though cash flow is often a much better measure for long-term growth than earnings.

Hopefully I'll get better at this ... we'll see.

Keep up with One Guy's Investments, Free Subscription
Enter your email address:

Delivered by FeedBurner

Friday, November 18, 2005 -- Subscribe free

Can't resist the robot (ISRG)

Well, as we close out a very successful week in the markets, it turns out that I can no longer resist the siren song of Intuitive Surgical (ISRG). I've been researching them in some detail since buying my first two positions in recent months, and the information I find leads me to the same answer I had when it was at $70 ... then at $90. $109 is a lot of money, but it's still a reasonable price to pay for this kind of growth potential. I don't expect to keep buying it at $20 increments all the way up, though ... for me, this is a full position for now and I'll sit back and watch.

But I did buy some more today. Purchased Intuitive Surgical (ISRG) on November 18 for $109.02.

You can read my earlier writeups on Intuitive Surgical -- my first buy, and second -- if you're interested in all I've got to say. I was first turned on to them by a Fool newsletter, and I have now gotten over my initial fear of paying too much for these shares.

There are a few caveats: It's still not cheap, and this is betting against the analysts to some extent -- they're predicting pretty flat sales and taxes due in 2006 for a forward PE of around 70 according to Yahoo Finance, which I think is extremely pessimistic. But they're probably smarter than I am, so buyer beware -- because as long as I maintain faith in management and the long term potential of this business, I'm not selling even if the analysts are right.

Patients are looking for this kind of minimally invasive surgery now, and we appear to be at a tipping point where it is prevalent enough (about 300 systems installed) that patients may begin to demand or expect it. And for all intents and purposes, they've got not only first-mover status in this area, but a monopoly.

Even so, Intuitive thinks they've hit less than 10% of their addressable market. And add to that the fact that those 300 or so systems are spread around about 230 hospitals in the US and maybe 30 or so elsewhere in the world (they just sold their first in China .. but even Australia only has two, and the UK one), and you can see that there's also ample room for selling multiple systems to the larger hospitals who perform the lion's share of major surgeries.

Hospital centers everywhere are releasing press releases or web pages that brag about their experience in robotic surgery ...

like Penn ...

or Shawnee Mission in Kansas ...

or the Henry Ford Health System in Michigan...

or Swedish Medical Center in Seattle ...

And it's showing up in regular advertising -- like this commercial from the DC Urology center at GWU (video).

There's even a robotic surgery blog from a doctor in New Jersey -- and he's predicting an almost exponential increase in the number of da Vinci surgeries he will perform.

If you don't know much about the field, a class at Brown University did an interesting looking report that has a lot of details -- it's slightly out of date, but well worth reviewing. Also a little out of date, a Business Week article from March provides a nice overview.

The success of the da Vinci system with prostatectomies is, I believe, just the first wave. That was the first major type of surgery for which FDA approval was granted and the first to reach a critical mass of trained surgeons and happy patients. Intuitive Surgical even has a special website just for patient information on the da Vinci prostatectomy.

But there are other types of surgeries performed every day in the US that could benefit from these minimally invasive techniques -- heck, those with strong stomachs could have watched a live heart valve surgery using the da Vinci back in January. And In March, doctors discovered that the da Vinci can be very effective in treating Oral cancer and doing other otolaryngological surgeries.

To sum up my investment philosophy for ISRG, and why I think the growth will continue (even if not at quite this same rate):

The growing BREADTH of hospitals and doctors who own and are trained on this machine is the first huge growth engine, but the growing DEPTH of procedures for which the machine is commonly used should be the second.


And don't forget, maintenance costs about $100,000 a year on these machines, and you can easily spend that much in accessories and replacement parts ... and doctor training can run a quarter of a million dollars, though I understand it's usually included in the purchase price. That $100,000 of high-margin income for ISRG will grow as each machine performs a larger number of surgeries of different types, and the overall steady income from this source will grow significantly as each new system is brought online.

I intend to hold these shares for many years and enjoy the ride, though I fully expect that this rapid growth will come with some hiccups along the way (and sometime over the next few months I'll probably regret that I didn't wait to fill out my position).

And remember -- my purchase today probably means it will drop on Monday, as I've recently seen with Shanda (SNDA) and Cryo-Cell (CCEL), so keep your eyes open for a great buying opportunity.



Labels: ,

Keep up with One Guy's Investments, Free Subscription
Enter your email address:

Delivered by FeedBurner

Comments:
As far as robots are concerned, I visited FARO on the Fabtech Show two days ago, they seem to be catching a lot of attention and they looked to me as a good company.

But you can't really judge a company on 10 minutes at a trade show.

Irobot, IRBT got its IPO recently also, it might be worth following
 
I'd be interested to hear what else you think about FARO, since I've never actually seen their products. Management has made me nervous this year by overpromising and underdelivering, but I still like the the fundamentals of the business and I'm holding on to the FARO shares I bought last winter.

I'm down about 30% on my FARO shares so far this year, and I'll definitely be keeping an eye on them to see if they can right the ship and get the kind of growth in earnings next year that they had expected for this year.
 
Well i'm not a specialist in their field, but they seemed to have an agressive sales policy (big booth, tons of machines exposed, invitations to visit their plants) and definitely received a lot of visitors on their booths.

As far as seeing their products, they mostly consist on robot arms that weld, assemble, cut or fold metal. Oh, and they are blue (very important detail, isn't it)

From what I know about manufacturing in general, products like theirs (basically automats and x-axes arms robots etc) should be more and more used as time goes on, but it's true that it's hard to compete with the big guys if you're a small company.

I can't promise it's going to be the next big thing, but if management is good, there is room for growth, hold on to your shares.
 
Post a Comment



<< Home

New feature, and what to buy now (ISRG, IMAX)?

After yesterday's great performance, I was inspired to add to the site my full portfolio (not including the boring 'ol mutual funds that are ripening in several retirement accounts). The post below this lists all the individual stocks I own (and a couple ETFs/CEFs), along with my average cost and, in most cases, the date of my most recent purchase. I'll update it every now and again.

This week has been pretty interesting -- especially yesterday. It's very unusual for me, with a portfolio of about 40 individual stocks, to see the overall portfolio move as much in one day as it did yesterday, up 2.5%. A few real standouts in there, including Overstock with their latest response on the lawsuits, but on the whole it was just a day with a ton of solid 3-5% gainers. Very nice to see. Hopefully I won't soon see quite that much movement on the downside in the near future.

Looking at a few candidates for new money today or early next week -- at the top of my list now are ISRG and IMAX, so I guess I'm fixated on the "I"s in my portfolio. ISRG I might just be irrationally exuberant about, but I am trying to decide whether the risk of waiting until they report their next quarter (typically a soft time for them) is worth it. If they don't disappoint, I'd hate to have to pay $140 for the shares instead of the $105 or so I might get it for these days.

IMAX is a bit of a risk for waiting, too -- they're still down a little bit after their somewhat soft earnings release, but future growth looks great with the growing installed base of theaters and their backlog. The short term question is, will Harry Potter get investors excited again and should I buy before we see those box office numbers? Or, as is so often the case with the entertainment producers, will we see a selloff on the news (see DWA, MVL and how their stocks have reacted to recent film openings). IMAX is a different kind of company, to be sure, but with the CEO on CNBC this morning talking up the sellouts I'm tempted to wait and see if I can get a better price after the Potter news is out.

As usual, I'll let you know what I decide to do. Happy investing.

Keep up with One Guy's Investments, Free Subscription
Enter your email address:

Delivered by FeedBurner

Current Portfolio -- Nov. 17, 2005

Ticker

Trade Date (most recent)

Average cost

Last price

(as of 11/17

Gain (as of 11/17)

AKAM

24-Jun-05

14.26

17.02

18.17%

BRK-B

7-Mar-05

3,005.00

2,950.10

-2.64%

CCEL.OB

16-Nov-05

3.89

3.85

-2.81%

CHS

26-Aug-05

35.05

45.33

24.40%

CKCM

-

16.06

26.7

59.80%

CVTX

19-May-05

21.01

25.88

22.02%

DWA

28-Mar-05

35.49

25.98

-27.25%

DWRI

7-Jul-05

18.02

5.4

-70.66%

EWY

7-Jul-05

31.90

40.82

24.70%

EXEL

-

8.13

8.32

0.37%

FARO

21-Jan-05

27.29

18.83

-31.00%

FORM

20-Jan-05

22.81

25.5

11.79%

GOOG

26-Jan-05

193.93

402.41

105.86%

IFN

7-Jul-05

30.15

39.68

28.07%

IMAX

18-Aug-05

9.90

8.85

-12.31%

ISRG

-

78.19

106.87

34.23%

LGF

20-Jun-05

10.47

9.73

-9.28%

MIDD

24-Jan-05

47.74

78.4

64.22%

MVL

20-Jan-05

18.12

14.48

-20.09%

MYGN

21-Jul-05

19.33

19.12

-2.06%

NHC

25-Feb-05

34.20

37.84

6.08%

NTES

6-May-05

50.45

60.41

14.09%

NTO

20-May-05

2.14

2.63

14.99%

OSTK

28-Jan-05

53.15

36.7

-32.54%

PANL